Where science and business join for impact
The American Society of Hematology (ASH) is the world's largest professional society concerned with the causes and treatments of blood disorders. The Society provides multiple opportunities for corporations, foundations, and other organizations to engage with leading hematologists around the world and demonstrate support that advances the field of hematology. There are a variety of opportunities for industry to support the Society's educational programs and annual meeting materials and services. As a benefit for supporting ASH initiatives, priority points are awarded. These points determine your ranking and placement on the exhibit floor at future ASH annual meetings.
Business Development, Your Innovation Partners
Business Development works to foster meaningful relationships with all those who make curing blood-based disorders their priority. As the conduit for these partnerships, our team amplifies the specific strengths each interest group offers to create opportunities for engagement that highlights each stakeholder.
Just as blood is integral to all bodily functions, ASH is integral to facilitating dynamic progress in the fight to treat and eventually cure all hematologic disorders.
The ASH Research Collaborative (ASH RC) is a non-profit organization that was established by the American Society of Hematology (ASH) in 2018 to foster collaborative partnerships to accelerate progress in hematology, with the goal of improving the lives of people affected by blood diseases. The foundation of the ASH RC is its Data Hub, a technology platform that facilitates the exchange of information by aggregating research-grade data on hematologic diseases. The ASH RC Sickle Cell Disease Clinical Trials Network optimizes the conduct of clinical trials research in SCD and leverages the Data Hub to collect key information and identify gaps to advance SCD research and treatment.
The Corporate Friends Program is an opportunity for true partnership and open dialogue with the American Society of Hematology and offers an exclusive opportunity to form strategic connections while fostering excellence within the field. The program offers pioneering companies an opportunity to invest in the field of hematology on an annual basis.